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ABSTRACT
Objective The short isoform of thymic stromal
lymphopoietin (TSLP), a cytokine constitutively expressed
by epithelial cells, is crucial in preserving immune
tolerance in the gut. TSLP deﬁciency has been implicated
in sustaining intestinal damage in Crohn’s disease.
We explored mucosal TSLP expression and function in
refractory and uncomplicated coeliac disease (CD),
a T-cell-mediated enteropathy induced by gluten in
genetically susceptible individuals.
Design TSLP isoforms—long and short—and receptors
—TSLPR and interleukin (IL)-7Rα—were assessed by
immunoﬂuorescence, immunoblotting and qRT-PCR in
the duodenum of untreated, treated, potential and
refractory patients with CD. The ability of the serine
protease furin or CD biopsy supernatants to cleave TSLP
was evaluated by immunoblotting. The production of
interferon (IFN)-γ and IL-8 by untreated CD biopsies
cultured ex vivo with TSLP isoforms was also assessed.
Results Mucosal TSLP, but not TSLPR and IL-7Rα, was
reduced in untreated CD and refractory CD in
comparison to treated CD, potential CD and controls.
Transcripts of both TSLP isoforms were decreased in
active CD mucosa. Furin, which was overexpressed in
active CD biopsies, was able to cleave TSLP in vitro.
Accordingly, refractory and untreated CD supernatants
showed higher TSLP-degrading capacity in comparison to
treated CD and control supernatants. In our ex vivo
model, both TSLP isoforms signiﬁcantly downregulated
IFN-γ and IL-8 production by untreated CD biopsies.
Conclusions Reduced mucosal TSLP expression may
contribute to intestinal damage in refractory and
untreated CD. Further studies are needed to verify
whether restoring TSLP might be therapeutically useful
especially in refractory patients with CD.
INTRODUCTION
Thymic stromal lymphopoietin (TSLP) is a cytokine
produced mainly by epithelial cells and expressed
in the skin, lungs, thymus and intestinal mucosa.1
TSLP exerts its biological activities by binding to a
heterodimer formed by interleukin (IL)-7 receptor
(IL-7R)α and TSLP receptor (TSLPR), leading to
the phosphorylation and activation of signal trans-
ducer and activator of transcription (STAT)5.1–4
During homeostasis, enterocyte-derived TSLP
promotes the development of tolerogenic dendritic
cells,5 which in turn induce the differentiation of
naive T cells into Foxp3-positive regulatory T cells
(Treg) and block the development of T helper (Th)
Signiﬁcance of this study
What is already known on this subject?
▸ Epithelial-derived thymic stromal lymphopoietin
(TSLP) is an immunoregulatory cytokine playing
a crucial role in immune tolerance in the gut
via conditioning dendritic cells to expand
regulatory T cells (Treg), with consequent
inhibition of T-cell-derived cytokines, such as
interferon (IFN)-γ and interleukin (IL)-17A.
▸ Mucosal TSLP is reduced in Crohn’s disease, a
chronic intestinal disorder characterised by an
abnormal T helper (Th)1/Th17 response, and
this defect contributes to gut inﬂammation.
▸ In coeliac disease (CD), a chronic enteropathy
caused in genetically susceptible individuals by
the ingestion of gluten, villous atrophy is
induced by a T-cell-derived cytokine
upregulation, abnormal dendritic cell activation
and increased matrix-metalloproteinase (MMP)
production.
What are the new ﬁndings?
▸ In addition to the marked reduction in the
transcript levels of both long and short TSLP,
TSLP protein levels are markedly decreased in
the duodenal mucosa of untreated and
refractory patients with CD.
▸ The serin protease furin, which is overexpressed
in active CD mucosa, potently degrades long
TSLP.
▸ Short TSLP modulates inﬂammation in CD
mucosa, as shown by the ex vivo effect in
inhibiting IFN-γ and IL-8 production by
untreated CD biopsies.
▸ Untreated CD myoﬁbroblasts may be the target
of TSLP action, as proven by their expression of
TSLPR and IL-7 receptor (IL-7R)α, and respond
to long TSLP by producing lower amounts of
MMP-3 and IL-8.
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1 and Th17 cells.6 7 TSLP expression and function are impaired
in chronic intestinal inﬂammation, as shown by the observations
that epithelial TSLP expression is markedly reduced in inﬂamed
Crohn’s disease mucosa, and that normal dendritic cells cultured
with supernatants of Crohn’s disease epithelial cells show only a
limited ability to induce Treg development.5 Recently, two
human transcript variants of TSLP have been identiﬁed, namely
the long and short TSLP isoforms.8 9 Short TSLP is the main
TSLP isoform expressed under steady-state conditions and has
anti-inﬂammatory and antimicrobial properties.8 9
Coeliac disease (CD) is an enteropathy caused in genetically
susceptible individuals by the ingestion of gluten.10 Rather than
a single-disease entity, CD is considered a polymorphic spec-
trum of disorders ranging from potential CD, referring to
patients with normal small bowel mucosa and positive coeliac
serology, to refractory CD, a rare condition characterised by the
persistence of villous atrophy despite strict adherence to gluten-
free diet (GFD).10 11 The abnormal immune response in active
CD mucosa is sustained by the aberrant activation and differen-
tiation of naive T cells into Th1 and Th17 cells, which respect-
ively release high amounts of interferon (IFN)-γ and
IL-17A,12 13 ﬁnally causing, via upregulating the intraepithelial
lymphocyte cytotoxicity against enterocytes14 and the produc-
tion of tissue-damaging matrix metalloproteinases (MMPs),15
increased enterocyte apoptosis and subsequent villous
atrophy.10 16
The presence of a marked T-cell-derived cytokine upregula-
tion in active CD mucosa,17 together with the increased den-
dritic cell inﬁltration, activation and maturation observed in the
lamina propria of untreated patients with CD,18 led us to
hypothesise that a dysregulation of TSLP expression could be
implicated in this condition. On this basis, we explored TSLP
expression along the multifaceted clinical spectrum of CD, and
then functionally tested the ex vivo and in vitro effects of TSLP
isoforms on the immune response and the extracellular matrix
remodelling processes in CD mucosa.
MATERIALS AND METHODS
Patients and tissues
Well-oriented endoscopic biopsies were collected from the
second part of the duodenum of 64 patients with untreated CD
(mean age 35.7 years, range 19–66) and 50 patients with CD
after at least 12 months of GFD (mean age 42.3 years, range
21–70). Diagnosis was based on the positivity of serum anti-
endomysial and anti-tissue transglutaminase antibodies asso-
ciated with typical histopathological lesions, namely villous
atrophy, increased intraepithelial lymphocyte inﬁltration and
crypt hyperplasia.10 Among the 64 untreated patients with CD,
59 showed a B2 lesion and 5 showed a B1 lesion, according to
Corazza-Villanacci grading.19 Histological improvement was
documented in all treated patients with CD. Duodenal biopsies
were also obtained from eight patients with refractory CD
(three type 1 and ﬁve type 211; mean age 62.8 years, range
38–76) (table 1), four patients with potential CD (mean age
47.2 years, range 31–71) (table 2) and 43 control subjects
(mean age 43.6 years, range 19–73) undergoing endoscopy for
functional dyspepsia, negative for anti-endomysial and anti-
tissue transglutaminase antibodies and with normal histology.
Potential CD was diagnosed in the presence of an architecturally
normal small bowel mucosa despite persistent positivity of
serum coeliac antibodies.10 All potential patients with CD were
on a gluten-containing diet at the time of the biopsy, and they
are currently under a yearly endoscopic follow-up. Some of the
biopsies were processed for routine histology or embedded in
OCT Tissue-Tek (Sakura Finetek, Torrance, California, USA)
and snap frozen; others were used for organ culture or cell iso-
lation or homogenised for immunoblotting. Heparinised periph-
eral venous blood of six healthy volunteers (mean age
38.6 years, range 30–46) was collected.
Immunoﬂuorescence
Four 5-μm-cryostat sections were ﬁxed in cold acetone or in par-
aformaldehyde 4% for 20 min and incubated overnight at 4°C
with rabbit anti-TSLP (3 μg/mL; manufactured and kindly pro-
vided by Maria Rescigno’s lab; please see online supplementary
methods for details) or rabbit anti-TSLPR antibodies (1:50 dilu-
tion; Santa Cruz Biotechnology, Santa Cruz, California, USA).
Cy3-conjugated donkey anti-rabbit (1:400 dilution; Jackson,
West Grove, Pennsylvania, USA) and FITC-conjugated goat anti-
rabbit (1:500 dilution; Abcam, Cambridge, UK) were used as
secondary antibodies. Sections were counterstained by 40,6-
diamidino-2-phenylindole (1:1000 dilution; Life Technologies,
Paisley, UK), and analysed with a laser scanning confocal micro-
scope (FluoView FV1000; Olympus, Center Valley,
Pennsylvania, USA). Images (1024×1024 pixels) were acquired
with an oil immersion lens (60×1.4 NA Plan-Apochromat;
Olympus).
Counting of epithelial cells
For cell counts, 8–24 crypts were evaluated only if aligned
along the longitudinal axis such that the lumen of the crypt
could be seen along its length. Observation of epithelial cells
was performed using conventional light microscopy in a blinded
manner by the same expert observer. Counts were performed at
a constant magniﬁcation (20×) by counting with an ocular
linear graticule the number of epithelial cells placed in the epi-
thelial layer overlying a ﬁxed unit length (200 μm) of muscularis
mucosae, deﬁned by the length of the graticule (60 μm).
RNA extraction and analysis of mRNA expression by
quantitative RT-PCR
Reverse transcription (Im-PromII, Promega, Southampton, UK)
on 1 μg total RNA extracted from biopsies was performed, and
cDNA was used for PCR. Primer sequences were as follows:
TSLP forward, 50-CCCAGGCTATTCGGAAACTCAG-30, and
reverse, 50-CGCCACAATCCTTGTAATTGTG-30 (these primers
do not distinguish between the two TSLP isoforms); long TSLP
forward, 50-CACCGTCTCTTGTAGCAATCG-30, and reverse,
50-TAGCCTGGGCACCAGATAGC-30; short TSLP forward,
50-CCGCCTATGAGCAGCCAC-30, and reverse, 50-CCTGAGT
AGCATTTATCTGAG-30; TSLPR forward, 50-AGAGCAGCGA
GACGACATTC-30, and reverse, 50-CCGGTACTGAACCTCAT
AGAGG-30. Typically, 40 cycles of 20 s at 95°C and 20 s at
60°C, followed by the thermal dissociation protocol for Fast
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ Our ﬁndings strengthen the key role of TSLP in modulating
immune and damaging mechanisms in the inﬂamed gut, and
may open new therapeutic perspectives in patients with CD
aimed at re-inducing immune tolerance towards gluten via
restoring TSLP function especially in refractory patients with
CD, who no longer respond to a gluten-free diet.
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SYBR green detection. PCR reactions were normalised by
expression analysis of GAPDH or cytokeratin 18 (CK18) with
the following primers: GAPDH forward, 50-ATCAGCAATGCC
TCCTGCAC-30, and reverse, 50-TGGCATGGACTGTGGTCA
TG-30; CK18 forward, 50-TGATGACACCAATATCACACGAC-30,
and reverse, 50-TACCTCCACGGTCAACCCA-30.20
Organ culture
Biopsies were placed in 24-well plates (VWR International,
Lutterworth, UK) in 300 μL serum-free HL-1 medium
(Cambrex BioScience, Wokingham, UK) supplemented with
100 U/mL to 100 μg/mL penicillin-streptomycin solution (Life
Technologies), and cultured at 37°C, 5% CO2, with or without
50 ng/mL long TSLP (aa 29–159, mw 15 kDa, Uniprot:
Q969D9; R&D Systems, Abingdon, UK) or 50 ng/mL short
TSLP (manufactured and kindly provided by Maria Rescigno’s
lab; please see online supplementary methods for details). After
24 h culture, biopsies and supernatants were stored at −70°C.
Lamina propria mononuclear cell isolation
Lamina propria mononuclear cells (LPMCs) were isolated from
duodenal biopsies, as previously described.18 Cells were not
used if viability did not exceed 90%.
ELISPOT
The 96-well polyvinylidene diﬂuoride-backed ELISPOT plates
(Millipore, Bedford, Massachusetts, USA) were coated with
15 μg/mL anti-IFN-γ antibody (Mabtech, Stockholm, Sweden)
and incubated overnight at 4°C. LPMCs resuspended in AIM-V
medium (Life Technologies) were added (2×105 cells/well, in
triplicate) to the pre-coated plates with or without 50 ng/mL
long TSLP (R&D Systems) in the absence or presence of soluble
anti-CD3 (Mabtech) and anti-CD28 (eBioscience, San Diego,
California, USA) antibodies, both at 1 μg/mL. Plates were
incubated overnight at 37°C, 5% CO2. Next, 1 μg/mL biotiny-
lated anti-IFN-γ antibody (50 μL/well; Mabtech) was added.
After 2 h, streptavidin alkaline phosphatase conjugate (1:1000
dilution; Mabtech) was added to the wells and plates were incu-
bated at room temperature for 2 h. Next, 100 μL/well of
chromogenic alkaline phosphatase substrate (1:25 dilution;
Bio-Rad Laboratories, Hercules, California, USA) was added.
The colorimetric reaction was stopped after 30 min with water,
then plates were air-dried. Spot-forming cells were counted
using an ELISPOT counter (Millipore).
Myoﬁbroblast isolation and culture
Myoﬁbroblasts were isolated from biopsies as previously
described21 and were used at passage 4–6. Subconﬂuent mono-
layers of myoﬁbroblasts seeded in 12-well plates (1×105 cells/
well) were starved for 24 h at 37°C, 5% CO2 before incubation
for 24 h at 37°C, 5% CO2 with 50 ng/mL long TSLP (R&D
Systems).
ELISA
IFN-γ and IL-8 in culture supernatants were measured using
ELISA kits (R&D Systems).
TSLP cleavage assay
Long TSLP (1 μg/mL; R&D Systems) was co-incubated for 24 h
at 37°C, 5% CO2 with 0.2–200 U/mL furin (Sigma-Aldrich,
Poole, UK), or with complete RPMI-1640 (Sigma-Aldrich) or
serum-free HL-1 (Cambrex BioScience) medium, or with super-
natants of biopsies cultured ex vivo for 24 h. Effects on TSLP
integrity and function were evaluated in cleavage reaction pro-
ducts by immunoblotting for TSLP and by bidirectional mixed
lymphocyte reaction (see online supplementary methods for
details), respectively.
Table 1 Clinical and pathological features of eight patients affected by refractory coeliac disease (RCD)
Patient Sex
RCD
type
Associated
complication
Age at CD
diagnosis
(years)
Age at RCD
diagnosis
(years)
Duration of
GFD (years)
HLA
status
Histological
grading17
CD8+/
CD3+
IELs
Monoclonal
TCR-γ gene
rearrangement Therapy
1 M 1 None 71 71 2 DQ2 B1 NA Present Steroids
2 F 2 UJI 60 63 9 DQ2 B1 ↓↓ Absent Steroids
3 F 2 None 63 64 1 DQ2 B2 ↓↓ Absent Surgery
4 F 2 None 40 54 14 DQ2 B2 ↓↓↓ Present Steroids
5 M 2 None 55 57 3 DQ2 B1 ↓ Present Steroids
6 M 1 None 75 76 1 DQ2 B2 ↓↓ Absent Steroids
7 F 1 None 24 37 13 DQ2 B2 Normal Absent Steroids
8 M 2 UJI 64 65 1 DQ2 B1 ↓↓ Present Steroids
F, female; GFD, gluten-free diet; HLA, human leucocyte antigen; IEL, intraepithelial lymphocyte; M, male; NA, not available; TCR, T cell receptor; UJI, ulcerative jejunoileitis; ↓, slightly
decreased; ↓↓, moderately decreased; ↓↓↓, markedly decreased.
Table 2 Clinical and pathological features of four patients affected by potential coeliac disease (PCD)
Patient Sex Associated diseases
Age at PCD
diagnosis (years)
Disease
duration (years)
HLA
status
Dietary
regimen
Histological
grading17
Development
of overt CD
1 F None 32 1 DQ2 GCD A Not yet
2 M Autoimmune thyroiditis 55 2 DQ2 GCD A Not yet
3 M Dermatitis herpetiformis 71 0 DQ2 GCD A Not yet
4 F Dermatitis herpetiformis 31 1 DQ2 GCD A Not yet
F, female; GCD, gluten-containing diet; HLA, human leucocyte antigen; M, male.
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Immunoblotting and immunoprecipitation
Immunoblotting was performed according to a modiﬁed
method described previously.22 Proteins (100 μg) or cell super-
natants (15 μL) were loaded and subjected to 10% SDS-PAGE
under reducing conditions, followed by nitrocellulose (Bio-Rad
Laboratories) transfer. The following anti-human primary anti-
bodies were used: rabbit polyclonal anti-TSLP (0.2 μg/mL;
Abcam), mouse anti-TSLPR (1:200 dilution; Santa Cruz
Biotechnology), rabbit anti-IL-7Rα (1:1000 dilution; Abcam),
rabbit anti-phospho-STAT5 (1:1000 dilution; Cell Signaling
Technology, Danvers, Massachusetts, USA), mouse anti-T-bet
(1:800 dilution; Abcam), rabbit anti-MMP-3 (1:500 dilution;
Abcam), rabbit anti-MMP-9 (1:1000 dilution; Abcam) and
rabbit anti-tissue inhibitor of matrix metalloproteinase (TIMP)-1
(dilution 1:1000; Abcam). Appropriate horseradish peroxidase-
conjugated antibodies (DAKO, High Wycombe, UK) were used
as secondary antibodies, and the reaction was developed with
the ECL plus kit (Amersham Biosciences, Little Chalfont, UK).
When required, blots were stripped and analysed for internal
loading controls using rabbit anti-STAT5 (1:1000 dilution; Cell
Signaling Technology) and rabbit anti-β-actin antibodies (1:5000
dilution; Abcam). Bands were quantiﬁed using an LKB Ultrascan
XL Laser Densitometer (Kodak, Hemel Hempstead, UK). For
immunoprecipitation experiments, total proteins were immuno-
precipitated with a rabbit polyclonal anti-TSLP (0.2 μg/mL;
Abcam), then analysed by immunoblotting for TSLP.
Statistical analysis
Data were analysed in the GraphPad Prism statistical PC
program (GraphPad Software, San Diego, California, USA)
using the non-parametric Mann–Whitney U (for comparison of
the in vivo data obtained in different groups of patients) or the
paired t test (for comparison of the ex vivo and in vitro data
obtained in different culture conditions). p<0.05 was consid-
ered statistically signiﬁcant.
RESULTS
In vivo mucosal TSLP expression
We ﬁrst determined duodenal TSLP expression by immunoﬂuores-
cence in untreated, treated, refractory, potential patients with CD
and controls (ﬁgure 1A). TSLP was absent in the epithelium and
lamina propria of untreated and refractory CD. Conversely, in
treated CD, potential CD and controls the majority of enterocytes
both at the epithelial surface and crypt level expressed TSLP.
Several TSLP-positive LPMCs were also found in treated CD,
potential CD and control mucosa. This is consistent with the cap-
acity of dendritic cells to produce TSLP.23 24 No difference in
TSLP expression was observed between treated CD, potential CD
and controls. We performed epithelial cell counts per unit length
of muscularis mucosae, and we observed a signiﬁcantly (p<0.05)
reduced number of epithelial cells in refractory (median 214,
range 195–234) and untreated CD (median 215, range 187–247)
compared with treated CD (median 246, range 205–266) and con-
trols (median 247, range 221–274). Immunoprecipitation con-
ﬁrmed immunoﬂuorescence data. A signiﬁcantly (p<0.05) lower
TSLP protein expression was observed in untreated and refractory
CD compared with treated CD and controls. TSLP protein did not
differ between untreated and refractory CD, and between treated
CD and controls (ﬁgure 1B). We did not observe any difference in
TSLP expression between type 1 and type 2 refractory CD. We
also evaluated mucosal TSLP transcripts (total: short+long TSLP
isoforms) by qRT-PCR (ﬁgure 1C). Upon normalisation for
GAPDH, TSLP mRNAwas signiﬁcantly reduced in untreated CD
compared with treated CD (p<0.0001) and controls (p<0.001).
No signiﬁcant difference was found in TSLP transcripts between
refractory CD and all the other groups. In order to neutralise the
possible bias due to the marked enterocyte loss occurring in active
CD, we normalised TSLP transcripts for the epithelial cell marker
CK18 (ﬁgure 1C). This normalisation conﬁrmed the statistically
signiﬁcant reduction of TSLP transcripts in untreated CD com-
pared with treated CD (p<0.0001) and controls (p<0.0005), and
showed a signiﬁcantly lower amount of TSLP mRNA in refractory
CD compared with treated CD (p<0.01) and controls (p<0.05).
The decrease in TSLP expression in six patients with CD evaluated
before and after GFD supports the concept that gluten withdrawal
normalises TSLP mucosal levels. We also measured transcripts of
long and short isoforms of TSLP in the duodenal mucosa of
untreated, treated CD and controls, and found that both the var-
iants are defective in active CD mucosa (see online supplementary
ﬁgure S1).
In vivo mucosal furin expression and ex vivo TSLP cleavage
Protease upregulation is common in active CD mucosa.15 25 Furin
is a ubiquitously expressed serine endopeptidase that has been
shown to cleave TSLP.26–28 Thus, we evaluated furin expression by
immunoblotting in mucosal homogenates (ﬁgure 2A). A signiﬁ-
cantly (p<0.05) higher furin expression was found in untreated
CD compared with treated CD and controls. Subsequently, we
assessed the effect of biopsy supernatants from refractory,
untreated, treated patients with CD and controls on TSLP integrity
(ﬁgure 2B). Furin degraded TSLP generating ∼10 and ∼3 kDa
fragments. TSLP degradation by furin was concentration-
dependent, as displayed by the increased intensity of the 10 kDa
fragment and the parallel decrease in intensity of the intact TSLP
band. Accordingly, at 24 h the band corresponding to intact TSLP
was lower after co-incubation with refractory and untreated CD
supernatants than with treated CD and control supernatants.
A higher intensity of the cleaved TSLP band after 2 h was observed
in refractory and untreated CD.
In vivo mucosal TSLPR and IL-7Rα expression
We then evaluated mucosal TSLPR expression by immunoﬂuores-
cence (ﬁgure 3A). Some cells in the lamina propria were
TSLPR-positive without differences among all the patient groups.
These data were conﬁrmed by TSLPR immunoblotting on
mucosal homogenates. To better understand the cellular target of
TSLP, we assessed the co-localisation of TSLPR with dendritic cell/
macrophage (CD11c, CD14) and T cell (CD3) markers in
untreated CD mucosa (see online supplementary ﬁgure S2).
TSLPR was expressed mainly by enterocytes, whereas it was
undetectable on CD3-positive intraepithelial lymphocytes and
LPMCs. We also found that some CD11c/TSLPR-positive LPMCs
were evident just underneath the epithelium. Moreover, a few
mononuclear cells co-expressed TSLPR and CD14 in the lamina
propria. IL-7Rα was expressed in the duodenal mucosa of all the
patient groups without differences among the different conditions
(ﬁgure 3B). TSLPR transcripts were not signiﬁcantly different
between all the patient groups, either upon normalisation for
GAPDH or CK18, and TSLPR expression did not change before
and after GFD in the six patients evaluated both at diagnosis and
after GFD (ﬁgure 3C). TSLPR mRNA and protein expression did
not differ between type 1 and type 2 refractory CD.
Ex vivo effects of TSLP on pSTAT5, T-bet and cytokines
Since TSLP exerts its function by STAT5 phosphorylation,1 we
evaluated whether TSLP was functional in our system by meas-
uring STAT5 phosphorylation in untreated CD biopsies cultured
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Figure 1 Reduced thymic stromal lymphopoietin (TSLP) expression in untreated and refractory coeliac disease (CD) mucosa. (A) TSLP expression
was evaluated by immunoﬂuorescence in the duodenum of a refractory, an untreated, a treated, a potential patient with CD and a control subject.
While in untreated and refractory CD mucosa TSLP expression was absent, in treated and potential CD and controls TSLP was expressed both at
epithelial and lamina propria level. Data are representative of staining performed in ﬁve refractory (two type 1 and three type 2), eight untreated,
eight treated, three potential patients with CD and eight controls. An isotype antibody was used as negative control. (B) TSLP protein, analysed by
immunoprecipitation in the duodenum of 5 refractory (two type 1 and three type 2), 16 untreated, 14 treated, 4 potential patients with CD and 14
controls. Examples in the upper panel are representative of all patients. Lower panel shows immunoblot densitometry. Results are mean±SEM. (C)
TSLP transcripts (total: short+long TSLP isoforms), quantiﬁed by qRT-PCR, in the duodenum of 5 refractory (2 type 1 and 3 type 2), 12 untreated, 15
treated, 4 potential patients with CD and 13 controls. Changes in transcript levels are normalised for either GAPDH or cytokeratin 18 (CK18).
Horizontal bars are mean values. au, arbitrary units.
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ex vivo with long or short TSLP (ﬁgure 4A). Long TSLP signiﬁ-
cantly (p<0.05) enhanced STAT5 phosphorylation ex vivo,
whereas short TSLP did not have any effect on STAT5 phos-
phorylation. Since TSLP inhibits Th1 cell development,5 we
evaluated the expression of the Th1-speciﬁc transcription factor
T-bet on biopsies from untreated patients with CD cultured ex
vivo with long or short TSLP (ﬁgure 4B). Both TSLP isoforms
signiﬁcantly (p<0.05) downregulated T-bet expression.
Compared with medium alone (mean 215.3±56.6 pg/mL), both
long and short TSLP signiﬁcantly (p<0.05) downregulated
IFN-γ production by untreated CD biopsies cultured ex vivo
(mean 61.2±19.6 pg/mL and 70.3±23.8 pg/mL, respectively)
(ﬁgure 4C). Long and short TSLP induced a signiﬁcant
(p<0.05) downregulation of IL-8 (mean 4052±1444 pg/mL
and 4408±1250 pg/mL, respectively) compared with unstimu-
lated conditions (mean 9829±1442 pg/mL) (ﬁgure 4C).
Additionally, IL-8 was signiﬁcantly decreased in culture superna-
tants of treated CD (mean 3227±1133 pg/mL, p<0.005) and
controls (mean 4383±1155 pg/mL, p<0.05) compared with
untreated CD (see online supplementary ﬁgure S3A).
In vitro effects of TSLP on IFN-γ release by LPMCs and
peripheral blood mononuclear cells
We then addressed whether LPMCs are target of TSLP. Untreated
CD LPMCs express both TSLPR and IL-7Rα (ﬁgure 5A). We
then cultured untreated CD LPMCs in ELISPOT plates with long
TSLP in the presence of anti-CD3/CD28 antibodies and evalu-
ated IFN-γ spot-forming cells. Long TSLP signiﬁcantly (p<0.05)
reduced IFN-γ spot-forming cells (mean 187.6±55.1/106) com-
pared with medium (mean 457.8±100.6/106). Anti-CD3/CD28
induced a signiﬁcant increase in mean IFN-γ spot-forming cells
(827.8±89.8/106) compared with medium (p<0.05) and long
TSLP (p<0.0005), and the addition of long TSLP signiﬁcantly
(p<0.05) downregulated IFN-γ spot-forming cells (mean 390.2
±120.1/106) compared with culture with anti-CD3/CD28 anti-
bodies (ﬁgure 5B). To explore the effects of furin-exposed long
TSLP on IFN-γ production, we co-cultured peripheral blood
mononuclear cells in bidirectional mixed lymphocyte reactions.
Long TSLP, at the concentration of 100 and 200 ng/mL, induced
a signiﬁcant (p<0.05) upregulation of IFN-γ production,
whereas furin-exposed long TSLP, at the concentration of 25 and
50 ng/mL, signiﬁcantly (p<0.05) downregulated IFN-γ produc-
tion compared with medium alone. Furin alone did not have any
effect on IFN-γ release. As expected, vitamin D3 induced a dose-
dependent reduction in IFN-γ concentration in culture superna-
tants. Short TSLP signiﬁcantly (p<0.05) reduced IFN-γ produc-
tion (see online supplementary ﬁgure S4).
Ex vivo and in vitro effects of TSLP on MMP-3, MMP-9 and
TIMP-1
In untreated CD, there is increased MMP activation,15 25 thus
we analysed the ex vivo effects of long TSLP on MMP and
TIMP-1 production by untreated CD biopsies. Long TSLP sig-
niﬁcantly (p<0.01) downregulated MMP-3, whereas it did not
change MMP-9 or TIMP-1 production (ﬁgure 6A). As intestinal
myoﬁbroblasts are an important MMP source,29 30 we assessed
the in vitro effects of long TSLP on untreated CD myoﬁbroblast
production of MMPs and TIMP-1. Untreated CD myoﬁbroblasts
expressed TSLPR and IL-7Rα, both when freshly isolated
(ﬁgure 6B) and at passage 4 (ﬁgure 6C). Supernatants of myoﬁ-
broblasts cultured with long TSLP showed signiﬁcantly
(p<0.01) lower MMP-3 levels than unstimulated myoﬁbro-
blasts, whereas long TSLP did not induce any signiﬁcant change
in MMP-9 and TIMP-1 production (ﬁgure 6D). Long TSLP sig-
niﬁcantly (p<0.005) downregulated IL-8 production by
untreated CD myoﬁbroblasts compared with medium only
Figure 2 Furin overexpression and increased thymic stromal lymphopoietin (TSLP) degradation in untreated coeliac disease (CD) mucosa. (A) Furin
protein was evaluated by immunoblotting in the duodenum of seven untreated and seven treated patients with CD, and seven controls. Examples in
the left panel are representative of all patients. Blots were stripped and analysed for β-actin. Right panel shows immunoblot densitometry. Results
are mean±SEM. (B) Effects of either recombinant human furin or supernatants of biopsies from three refractory, ﬁve untreated and ﬁve treated
patients with CD and four controls on TSLP integrity. 1 μg/mL recombinant human TSLP was co-incubated with either furin (0.2–200 U/mL) or biopsy
supernatants, then TSLP integrity was evaluated by immunoblotting on reaction products. Furin-mediated TSLP cleavage occurred in a
concentration-dependent manner and was mirrored by decreasing intensity of the band corresponding to intact TSLP. At the highest furin
concentration, a further ∼3 kDa TSLP fragment appeared. At 24 h, the band corresponding to intact TSLP is lower after co-incubation with refractory
and untreated CD supernatants than with treated CD and control supernatants. In parallel, we observed a higher intensity of the band
corresponding to cleaved TSLP after 2 h in refractory and untreated CD. Examples shown are representative of all patients. au, arbitrary units.
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Figure 3 Thymic stromal lymphopoietin receptor (TSLPR) and interleukin (IL)-7Rα expression in coeliac disease (CD) mucosa. (A) Mucosal TSLPR,
evaluated by immunoﬂuorescence, in the duodenum of a refractory, an untreated, a treated, a potential patient with CD and a control subject. No
difference was found in TSLPR expression both at epithelial and lamina propria level in all groups studied. Data are representative of staining
performed in ﬁve refractory (two type 1 and three type 2), eight untreated, eight treated, three potential patients with CD and eight controls. An
isotype antibody was used as negative control. (B) TSLPR and IL-7Rα protein, evaluated by immunoblotting, in the duodenum of 5 refractory (2 type
1 and 3 type 2), 16 untreated, 14 treated, 4 potential patients with CD and 14 controls. Examples in the upper panel are representative of all
patients. Blots were stripped and analysed for β-actin. Lower panels show immunoblot densitometry. Results are mean±SEM. (C) TSLPR transcripts,
quantiﬁed by qRT-PCR, in the duodenum of 5 refractory (2 type 1 and 3 type 2), 12 untreated, 15 treated, 4 potential patients with CD and 13
controls. Changes in TSLPR transcripts are shown after normalisation with either GAPDH or cytokeratin 18 (CK18). Horizontal bars are mean values.
au, arbitrary units.
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(from mean 218.5±37.2 pg/mL to 13.5±11.9 pg/mL) (see
online supplementary ﬁgure S3B).
DISCUSSION
TSLP, an immunoregulatory cytokine constitutively expressed by
enterocytes, plays an important role in preserving mucosal toler-
ance during homeostasis in the gut.31 Conversely, mucosal TSLP
deﬁciency has been reported in Crohn’s disease, and this contri-
butes to chronic inﬂammation due to the consequent impair-
ment in tolerogenic dendritic cell differentiation.5 20 In keeping
with the ﬁndings by Fornasa et al,9 we observed that both long
and short TSLP mucosal transcripts are reduced in active
patients with CD compared with treated CD and controls. In
the atrophic duodenal mucosa of both untreated and refractory
patients with CD, we observed a marked TSLP reduction both
at gene and protein levels. In parallel, we found a reduced
number of epithelial cells per unit length of muscularis mucosae
in refractory and untreated CD mucosa, suggesting that reduced
TSLP may be a consequence of enterocyte loss. However, TSLP
reduction in active CD was conﬁrmed upon normalising TSLP
transcripts for the epithelium-speciﬁc gene CK18, and this indi-
cates that this deﬁciency is at least in part irrespective of the epi-
thelial damage. There was no difference in mucosal TSLP
expression both at protein and mRNA levels between type 1
and 2 refractory CD. TSLP expression normalised in treated
CD, suggesting that TSLP deﬁciency might not be a primary
defect in CD. This concept is further supported by unchanged
TSLP content in architecturally normal potential CD mucosa.
As an additional mechanism to explain TSLP defect in CD,
we hypothesised an increased TSLP degradation by furin, a
Figure 4 Ex vivo effects of long and short thymic stromal lymphopoietin (TSLP) on cytokine production by untreated coeliac disease (CD) mucosa.
Recombinant human long or short TSLP were cultured with biopsies from six untreated patients with CD and after 24 h culture phospho-signal
transducer and activator of transcription (pSTAT)5 (A) and T-bet expression (B) was evaluated in mucosal homogenates by immunoblotting, while
interferon (IFN)-γ and interleukin (IL)-8 production (C) was evaluated on biopsy supernatants by ELISA. Blots for pSTAT5 and T-bet were stripped and
respectively analysed for STAT5 and β-actin. Examples shown are representative of all patients. Right panel shows immunoblot densitometry. Results
are mean±SEM. Cytokine levels are mean±SEM. au, arbitrary units.
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calcium-dependent serine endoprotease capable of cleaving
TSLP.26–28 Furin was overexpressed in active CD mucosa com-
pared with both treated CD and controls. We then veriﬁed in an
in vitro cleavage assay whether supernatants of duodenal biop-
sies could degrade long TSLP. Untreated and refractory CD
supernatants showed a higher TSLP-degrading ability compared
with treated CD and control supernatants, as shown by the
higher intensity of the cleavage fragment after 2 h and the
reduced intensity of the band corresponding to intact long
TSLP. Therefore, cleavage may represent an additional mechan-
ism accounting for TSLP deﬁciency in untreated CD.
TSLP exerts its functions by binding to the heterodimer
formed by IL-7Rα and TSLPR. We observed comparable levels
of both TSLPR and IL-7Rα in the duodenal mucosa of refrac-
tory, untreated, treated and potential CD and controls.
Moreover, we could detect both TSLPR and IL-7Rα in the
lysates from unfractionated duodenal LPMCs and myoﬁbro-
blasts from the duodenal mucosa of untreated patients with CD.
The evidence that TSLPR co-localises with CD11c and CD14
on the surface of LPMCs in untreated CD supports the notion
that TSLPR is expressed by mucosal phagocytes, in keeping
with the well-known increased lamina propria dendritic cell
inﬁltration in untreated CD.18
TSLP reduction in active CD mucosa may have important
immunological consequences. Since TSLP signalling through
TSLPR results in downstream STAT5 phosphorylation,32 we
evaluated pSTAT5 in untreated CD biopsies challenged with
long or short TSLP. Only long TSLP upregulated pSTAT5,
whereas short TSLP was unable to induce STAT5 phosphoryl-
ation, in keeping with previous observations.8 9 We observed
that both long and short TSLP downregulate T-bet expression
and IFN-γ production by untreated CD biopsies. Moreover, the
number of IFN-γ-producing untreated CD LPMCs, which
expressed TSLPR, was reduced by the culture with long TSLP,
in keeping with the demonstration that TSLP may exert its
action directly on mucosal T cells.23 33 These ﬁndings support
the concept that TSLP deﬁciency in active CD may have a role
in upregulating the Th1 mucosal immune response, which plays
a crucial role in the development of villous atrophy.10 12 13
While our results conﬁrm the anti-inﬂammatory properties of
short TSLP, the reduction of IFN-γ production observed upon
culture with long TSLP is in apparent contrast with the results
of Fornasa et al,9 who reported that the long isoform is respon-
sible for an increased IFN-γ production in human mixed
lymphocyte reaction. In the same type of in vitro experiment,
we observed that furin-exposed long TSLP induces a reduction
of IFN-γ release by peripheral blood mononuclear cells to a
similar extent as short TSLP. The effects of long TSLP on IFN-γ
production by untreated CD biopsies and LPMCs may derive
from TSLP proteolytic cleavage, in keeping with our results on
TSLP degradation by active CD organ culture supernatants and
furin. Additionally, both long and short TSLP reduced untreated
CD biopsy production of IL-8, a chemokine promoting immune
cell recruitment into inﬂamed gut, and which we showed to be
produced in excess by untreated CD biopsies grown ex vivo.
Based on recent ﬁndings showing a marked TSLP upregulation
in several chronic inﬂammatory disorders characterised by dysre-
gulated tissue remodelling,34–36 a role for TSLP in modulating
extracellular matrix turnover was proposed. Since abnormal
extracellular matrix turnover is implicated in promoting villous
atrophy in CD,15 25 37 we assessed the ex vivo inﬂuence of long
TSLP on MMP-3, MMP-9 and TIMP-1 release.38 TSLP addition
to active CD biopsies led to a signiﬁcant MMP-3, but not
MMP-9 and TIMP-1, reduction. As intestinal myoﬁbroblasts are
among the most important MMP-producing cell types,29 30 upon
having veriﬁed their expression of TSLPR and IL-7Rα in CD, we
evaluated long TSLP effect on production of MMPs by untreated
CD myoﬁbroblasts. TSLP markedly reduced MMP-3 production.
These ﬁndings suggest that TSLP deﬁciency may contribute to
tissue damage by upregulating MMP-3, conﬁrming the
Figure 5 In vitro down-regulatory effects of long thymic stromal lymphopoietin (TSLP) on interferon (IFN)-γ spot-forming untreated coeliac disease
(CD) lamina propria mononuclear cells (LPMCs). (A) TSLP receptor (TSLPR) and interleukin (IL)-7Rα protein, detected by immunoblotting, on lysates
of LPMCs isolated from two untreated patients with CD. Blots were stripped and analysed for β-actin. (B) Proportion of IFN-γ-secreting LPMCs from
the duodenum of ﬁve untreated patients with CD evaluated through ELISPOT assay after in vitro stimulation with recombinant human TSLP. The
photographs displayed in the upper panels, showing IFN-γ ELISPOTs derived from LPMCs unstimulated or stimulated with TSLP in the absence or
presence of anti-CD3/CD28 antibodies (αCD3/CD28), are representative of all experiments performed. The frequency of IFN-γ-secreting LPMCs is
shown in the lower panel as the mean number of IFN-γ spot-forming cells (SFCs) per 106 LPMCs corrected for background. Values are mean±SEM.
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pathogenic role of this protease in active CD.15 25 Finally, as
intestinal myoﬁbroblasts produce IL-8,39 we measured IL-8 pro-
duction by untreated CD myoﬁbroblasts following TSLP stimula-
tion. Long TSLP reduced IL-8 production by untreated CD
myoﬁbroblasts, highlighting a new role for such cells, considered
to have almost exclusively architectural functions so far.
Remarkably, our results on the effects of long TSLP in active CD
were obtained on biopsies and cell types, such as LPMCs and
myoﬁbroblasts, which are an important source of proteolytic
enzymes; therefore, we cannot exclude that the anti-
inﬂammatory properties of the long TSLP are the result of a
protease-cleaved peptide.
In conclusion, defective TSLP content in active CD mucosa
may contribute to the upregulation of T-cell-derived cytokines
and myoﬁbroblast-released matrix-degrading enzymes. The
potent action demonstrated by TSLP in dampening tissue
inﬂammation and damage in CD suggests that restoring TSLP
function might be therapeutically useful at least in refractory
patients with CD, who no longer respond to GFD.
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